gregmoehl: There are some serious differences between where we are now and we where in 2001. Two of the most important are that the human genome project is now finished (well, for all practical purposes, its finished), and ABI has a different leadership team now than it had in 2001. Very different technologies are going to be important over the next few years, and ABI doesn't have as big a lead in those as it did in the sequencing technologies that were the driving force before 2001.However, ABI has some great instruments that position it well for the present (MS and realtime pcr amongst others) and they have filed for patents on things that could be the next big things. One patent I saw recently (I don't have the number here at home) covers some things that are going to be the cutting edge technologies over the next few years, like very inexpensive, very high throughput QPCR. That, and ABIs sequencing history and current commitment to getting to a $1000 genome, are not going to hurt it, so the big question is whether the new management can create the 900 lb gorilla that ABI once was.srlasky
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar